Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 3-day drug license suspension order for a store located at Guthal Road, Mandya, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Mandya Circle, and received on 21 March 2026. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and the corresponding Rules, 1945. The company has disclosed a potential revenue loss of only Rs 0.37 lacs (approximately Rs 37,000) due to this suspension. Medplus operates hundreds of stores across India, so this relates to a single outlet in its network.
The financial impact is negligible at just Rs 37,000 in potential revenue loss, and the suspension lasts only 3 days for one store. This is unlikely to have any meaningful effect on the company's overall operations or stock price.